Introduction
Numerous biomarkers have been evaluated for the diagnosis, risk stratification, and management of heart failure (HF). B-type natriuretic peptide (BNP) and its amino-terminal fragment, NT-proBNP, have emerged as gold standard biomarkers in current HF guidelines.
1,2 Recommendations on novel biomarkers such as midregional pro-atrial natriuretic peptide (MR-proANP) or the peptide hormone adrenomedullin are less explicit or lacking, often due to limited evidence of incremental diagnostic or prognostic capacity.
Adrenomedullin is ubiquitously prevalent in cardiac, vascular, renal, pulmonary, and endocrine tissues, and has diuretic, natriuretic, vasodilatory, hypotensive, and angiogenic properties. 3, 4 Its short plasma half-life 3 limits diagnostic applicability, but an assay measuring midregional pro-adrenomedullin (MR-proADM), a bio-inactive more stable pro-hormone fragment, is available. 3 -5 In previous research, MR-proADM has shown independent prognostic value in cardiovascular diseases including chronic HF, 6 -10 acutely decompensated HF (AHF) following myocardial infarction, 11 coronary disease, 12 chest pain, 13 and stroke.
14 In acute dyspnoea, 15, 16 MR-proADM proved superior to both BNP and NT-proBNP in predicting short-term mortality risk and provided incremental prognostic information on 90 day mortality when added to these natriuretic peptides (NPs). 15, 16 Furthermore, MR-proADM levels were associated with cardiovascular risk factors and sub-clinical disease 17 and predicted adverse outcomes in non-cardiovascular conditions such as hypertension, 18 pneumonia, 19 chronic obstructive pulmonary disease 20 and renal disease. 21 Against this background, we aimed to characterize the specific and incremental value of MR-proADM compared with NT-proBNP and the more recently introduced MR-proANP, as well as with a clinical base model for risk stratification in patients discharged from hospital after an episode of AHF. Variables associated with MR-proADM baseline levels and with their changes over time were identified, and possible correlates of high/rising MR-proADM levels studied. Furthermore, the prognostic significance of high MR-proADM levels in the setting of low NP levels was assessed.
Methods

Patients and study flow
Participants of the Interdisciplinary Network Heart Failure (INH) programme 22 were eligible for this post-hoc analysis if they had baseline biomaterials available for MR-proADM determination. INH inclusion criteria were a hospitalization for acute cardiac decompensation, lacking evidence of new-onset structural heart disease (e.g. myocardial infarction), and a left ventricular ejection fraction (LVEF) ≤40% prior to discharge. All patients provided written informed consent to INH study participation. The study complied with the Declaration of Helsinki and was approved by all responsible ethics committees. Follow-up was six-monthly either during an outpatient visit or by telephone. Total follow-up was 18 months (100% complete).
Physician and hospital records, reports from patients and relatives, and death certificates were used to adjudicate hospital readmissions . 
Biomarkers
Biomaterials were collected before hospital discharge and during follow-up visits and stored at −80 ∘ C. All biomarkers were analysed after follow-up and endpoint adjudication had been completed.
MR-proADM was measured using a commercial fluoroimmunoassay (BRAHMS MR-proADM KRYPTOR, BRAHMS GmbH, Hennigsdorf, Germany). The lower detection limit of the assay was 0.08 nmol/L; functional assay sensitivity is 0.12 nmol/L. Intra-assay coefficients of variation at 0.5/5 nmol/L were 3%/3.5%, and inter-assay coefficients of variation at 0.5/5 nmol/L were 8.5%/6.5%.
NT-proBNP was measured with the IMMULITE 2000 system (Siemens Healthcare Diagnostics GmbH, Eschborn, Germany); the inter-assay coefficient of variation was 6.4% at a concentration of 35.6 pg/mL and 4.0% at a concentration of 1430 pg/mL. The assay measuring range was 21.3-32 855 pg/mL.
MR-proANP was determined using a commercial fluoroimmunoassay (BRAHMS MR-proANP KRYPTOR; BRAHMS GmbH, Hennigsdorf, Germany; lower detection limit 6.0 pmol/L). The intra-assay coefficient of variation was 10% and 20% for samples containing MR-proANP 23-3000 pmol/L and 18-22.8 pmol/L, respectively. At 65 and 18 pmol/L MR-proANP, the interassay coefficients of variation were 10% and 20%, respectively.
Echocardiography
Echocardiography was performed as part of routine patient care but using a pre-specified protocol based on current recommendations. 24 Left ventricular end-diastolic diameter (LVEDD) was measured from M-mode echocardiograms obtained in the left parasternal long axis view. LVEF was derived from apical two-and four-chamber views using Simpson's biplane or single plane method. At follow-up, care was taken to precisely reproduce the cross-sections on which baseline measurements were based. Remodelling was defined as any increase in LVEDD plus any decrease in LVEF; reverse remodelling was defined as any decrease in LVEDD plus any increase in LVEF.
Statistical analysis
Variables are given as mean (standard deviation), median (interquartile range), or number of patients (%) as appropriate. To identify associations between MR-proADM levels and clinical variables, patients were grouped according to baseline MR-proADM tertiles. Group differences were tested using analysis of variance, Kruskal-Wallis test, or 2 test, respectively.
Clinical variables with known prognostic impact in HF were entered into a 'base model' which comprised age, sex, NYHA class (III/IV), anaemia (haemoglobin <12 mg/dL in females, <13 mg/dL in males), body mass index, LVEF, and renal function. Since the increase in morbidity and mortality associated with renal dysfunction occurs mostly at estimated glomerular filtration rate (eGFR) levels <60 mL/min/1.73 m 2 , 25 this cut-off was selected for the current analysis. The potential of the base model and of each of the investigated biomarkers alone or combined with the base model, as well as the incremental value of adding MR-proADM to the base model and either of the two NPs, regarding outcome assessment was evaluated using Cox proportional hazards regression analysis. Biomarker levels were log 10 -transformed and entered as continuous variables. Hazard ratios (HR) and 95% confidence intervals (CI) are reported. To account for potential effects of the INH study intervention, this variable was also added to the base model. Event-free patients were censored at 540 days.
To assess the incremental prognostic yield of adding MR-proADM to a model containing the base model and NT-proBNP, as well as of serial MR-proADM sampling, nested likelihood ratio tests and the class-free net reclassification rate 26 were calculated. For illustrative purposes, risk calculation tables are given using appropriate risk categories, 27 which were defined based on the observed overall mortality in the study cohort.
We further aimed to assess the potential of each individual biomarker to estimate the risk of cardiac and non-cardiac death. To account for competing risks we used a Fine-Gray sub-distribution hazard model, as recently recommended, 28 to estimate event incidence or predict prognosis in the presence of competing risks (i.e. cardiac and non-cardiac death). 29 In contrast to standard Cox models, which do not account for the fact that cardiac and non-cardiac death are competing risks and thereby overestimate total mortality risk, this approach takes into account the increased risk of death attributable to competing risks (other than cardiac) in elderly populations like the HF patients included in this trial. In each model, the base model and one of the biomarkers were included. Only in this analysis, biomarkers were dichotomized at the upper tertile thus allowing for graphical visualization of the sub-distribution hazard in patients with low vs. high biomarker values. Cumulative incidence functions were estimated and are shown for cardiac and non-cardiac deaths, respectively.
All test results are two-tailed. P-values <0.05 were considered statistically significant. Statistical analysis was performed using R 3.1.1. 30 
Results
Patients and biomaterials
A total of 917 INH participants were included in the present post-hoc analysis, all of whom had MR-proADM measured at baseline [662 (72%) men and 255 (28%) women, with a mean age of 66.7 ± 11.9 and 71.3 ± 12.8 years, respectively, P < 0.001]. At the 6 and 18 month follow-up (F6; F18) all-cause death had occurred in 91 (9.9%) and 185 (20.2%) patients [cardiac death n = 57 (6.2%) and n = 98 (10.7%)], and rehospitalization in 98 (10.7%) and 506 (55.2%) patients, respectively. F6 MR-proADM was available in 599 patients (65.3%) only, because 91 (9.9%) had died and 227 (24.8%) had telephone follow-up only. Non-attending survivors were older, more severely ill, and more often female (Supplementary material online, Table S1 ). F18 MR-proADM assessment was feasible in 477 patients (52%). the prevalence of cardiac or non-cardiac comorbidities, heart rate, and NP levels increased, and LVEF decreased. Subjects with MR-proADM values in the upper tertile took less often angiotensin-converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs), and mineralocorticoid receptor antagonists, and more often diuretics. In linear multiple regression analysis, higher MR-proADM levels were associated with older age, renal dysfunction, anaemia, leucocytosis, peripheral artery disease/stroke, depression, and NYHA classes III/IV. Although the proportion of women increased significantly across tertiles, linear multiple regression analysis showed no significant association of MR-proADM levels with sex (Supplementary material online, Table S2 ). LVEF was inversely correlated with baseline MR-proADM (Supplementary Table S2 ). Furthermore, higher ACEi, ARB, and beta-blocker doses at baseline and F6 were associated with lower MR-proADM, NT-proBNP, and MR-proANP levels (Supplementary material online, Figures S1-S3 ). Nevertheless, neither the quality of baseline HF therapy (proportion of the guideline-recommended target equivalence dose of each drug) nor the extent or direction of changes in drug doses during the study were associated with changes in biomarker levels between baseline and F6 (Supplementary material online, Figures S4 and S5 ).
Predictors of baseline midregional pro-adrenomedullin levels and changes at follow-up
Prognostic significance of midregional pro-adrenomedullin vs. natriuretic peptides
Over 18 months' follow-up, MR-proADM showed the highest prognostic yield. Concordance indices (C-indices) for all-cause and cardiac mortality, or rehospitalization, were 0.724, 0.770, and 0.597, respectively. These results remained materially unchanged after adjusting for the base model ( Table 2 and Supplementary material online, Tables S3-S10). Inclusion of the study intervention in the base model did not significantly alter these results (data not shown). For all-cause and cardiac death prediction, neither NP improved models including MR-proADM, whereas inclusion of MR-proADM improved Cox models containing either MR-proANP or NT-proBNP ( Table 2 ). The class-free net reclassification index (95% CI) for adding MR-proADM to a model containing the base model plus NT-proBNP was 0.44 (0.14 − 0.74) overall, 0.26 (−0.03 to 0.55) for patients who died and 0.18 (0.10 − 0.27) for 18 month survivors. Table 3 illustrates reclassification results for all-cause mortality with application of appropriately defined risk categories. 27 Comparable findings were obtained for cardiac mortality and all-cause rehospitalization (data not shown).
Using the upper tertile as cut-off in a Fine-Gray sub-distribution hazard model, 28 both higher MR-proADM and NT-proBNP levels predicted cardiac death (HR 3.0, 95% CI 1.7 − 5.4; P < 0.001 and HR 2.3, 95% CI 1.4 − 3.7; P < 0.001, respectively). MR-proADM, but not NT-proBNP, levels predicted non-cardiac death (HR 1.8, 95% CI 1.0 − 3.1; P = 0.043 and HR 1.0, 95% CI 0.6 − 1.8; P = 0.970, respectively). MR-proANP did not discriminate between cardiac and non-cardiac death (HR 1.5, 95% CI 1.0 − 2.5; P = 0.077 and HR 1.4, 95% CI 0.8 − 2.4; P = 0.190, respectively). Estimated cumulative incidence functions displaying the biomarkers' discriminative ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index (n = 911); COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; LVEDD, left ventricular end-diastolic diameter, measured from M-mode echocardiography; LVEF, left ventricular ejection fraction, derived from two-dimensional echocardiography; MR-proADM, midregional pro-adrenomedullin; MR-proANP, midregional pro-atrial natriuretic peptide; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; PAD, peripheral arterial disease.
potential regarding cardiac and non-cardiac deaths are shown in Figure 1 .
Prognostic significance of serial biomarker assessment
At baseline, median levels of MR-proADM, NT-proBNP, and MR-proANP were 0.78 (0.60-1.14) nmol/L, 2388 (868-5384 bootstrap-corrected C-index from 0.772 to 0.781; P < 0.001). Conversely, inclusion of baseline MR-proADM into the model containing F6 MR-proADM values had no incremental prognostic significance (P = 0.419). Similar results were found for all-cause rehospitalization (added 2 32.4; bootstrap-corrected C-index increase 0.634 to 0.660; P < 0.001; Table 4 ).
Addition of F6 MR-proADM to the baseline model plus baseline MR-proADM was associated with class-free net reclassification indices of 0.48 (95% CI 0.19-0.78) in the total cohort, 0.22 (95% CI −0.06 to 0.5) in patients who died at 6-18 months, and 0.27 (95% CI 0.19-0.35) in 18 month survivors. 27 Findings were similar for all-cause rehospitalization (data not shown).
The lower number of cardiac deaths in particular between the 6 and 18 month follow-ups precluded corresponding analyses for that endpoint.
Serial biomarker assessment and left ventricular remodelling
Using the median F6 MR-proADM value as a cut-off, 295 patients had persistently low MR-proADM levels, 63 had rising levels, 45 had falling levels, and MR-pro-ADM levels were persistently . Table S11 ), whereas LV reverse remodelling was significantly more common in patients with low MR-proADM at both baseline and F6 (Supplementary material online, Table S12 ). In contrast to NPs, baseline MR-proADM did not predict cardiac reverse remodelling within the subsequent 6 months (logistic regression, P < 0.001 for both NPs vs. P = 0.784 for MR-proADM), whereas all three biomarkers were at F6 significantly predictive of reverse remodelling in the following year (P < 0.001 for both NPs, P = 0.003 for MR-proADM).
Discussion
Using a rigorous and comprehensive contemporary statistical approach, this post-hoc analysis from the INH programme suggests better performance of MR-proADM compared with both NT-proBNP and MR-proANP for individual patient risk assessment after AHF. Individually, and also when added to a clinical base model, MR-proADM had better C-statistics than these Tables show numbers of subjects changing the risk category when information on baseline MR-proADM levels was added to the prognostic information contained in the base model plus NT-proBNP. For definition of base model see Table 2 .
Green cells: patients appropriately reclassified by inclusion of MR-proADM, i.e. to higher risk category if experiencing death, and to lower risk category if surviving 18 month follow-up. Orange cells: patients inappropriately reclassified. Grey cells: patients remaining in the same category. The chosen risk categories are for illustrative purposes only. Among subsequently dying patients (left side), 12 were reclassified in a higher risk category (green), whereas 7 were reclassified to a lower risk category (orange). Amongst survivors (right side), 89 patients were reclassified to a lower (green) and 68 to a higher risk category (orange). MR-proADM, midregional pro-adrenomedullin; NT-proBNP, N-terminal pro-B-type natriuretic peptide. Table 2 . BL, baseline; F6, 6 month follow-up; MR-proADM, midregional pro-adrenomedullin.
gold standard biomarkers regarding prediction of all-cause and cardiac mortality and, to a lesser extent, all-cause rehospitalization. In contrast to NT-proBNP, which only predicted cardiac death, MR-proADM was capable of predicting both cardiac and non-cardiac death in a Fine-Gray sub-distribution hazard model. 28 In addition, adding MR-proADM to the clinical prediction model including NT-proBNP improved risk stratification significantly throughout the entire 18 month observation period. High MR-proADM levels were not only associated with more impaired LV function and various comorbidities, but also with a lower quality of HF therapy. While low MR-proADM levels predicted reverse LV remodelling at F6, patients with high or increasing MR-proADM showed a trend towards more LV remodelling. Although median MR-proADM levels remained unchanged over time, serial measurements improved its prognostic significance in individual patients.
A recent systematic review 4 studies include the Biomarkers in Acute Heart Failure (BACH) trial 15, 16 and the PRIDE study, 31 as well as the work of von Haehling et al. 8 and Adlbrecht et al., 7 which all showed the prognostic value of MR-proADM as superior to NPs and demonstrated an improvement in prognostic value with serial MR-proADM measurements in patients with HF. In line with our results, the Multinational Observational Cohort on Acute Heart Failure (MOCA) study showed that the prognostic utility of MR-proADM was superior to that of several other biomarkers, including cardiac troponins as well as the NPs. 9 In addition, the results of the VERyfing DYspnea trial showed that serial MR-proADM measurements improved the prognostic significance of this biomarker in patients with dyspnoea in the emergency department. 32 Negative findings in a limited number of studies (e.g. Gegenhuber et al. 33 ) might be the result of smaller sample size or methodological issues.
Our findings extend current knowledge in several respects. First, we could demonstrate a superior prognostic capacity of D) and MR-proANP (E and F) levels, Fine-Gray regression, 28 adjusted for base model, n = 878. In (D), the hazard ratio (HR) values for both groups were 1.00, meaning that the curves overlap. Therefore, a dashed line is used to visualize the two identical incidence functions.
MR-proADM compared with both NPs in the early phase after hospitalization for AHF as well as in the subsequent year when patients were more stable. Second, we showed that throughout the entire follow-up period neither NP provided incremental value over MR-proADM in predicting adverse clinical outcomes, whereas inclusion of MR-proADM improved models containing either MR-proANP or NT-proBNP. Furthermore, MR-proADM proved capable of identifying patients at high risk of both cardiac and non-cardiac death. In the setting of low NP, patients with high MR-proADM experienced non-cardiac death more frequently. An explanation for this latter observation might be that whereas NPs are mainly released in response to augmented cardiac wall stress, 34 MR-proADM is also elevated in various non-cardiac disorders and risk states. 4, 20 In our study, higher MR-proADM levels were not only associated with worse HF symptoms and cardiac function, but also with a higher prevalence of non-cardiac comorbidities known to impact adversely on outcomes and promote HF progression. Our data suggest, therefore, that MR-proADM reflects the risk associated with these systemic manifestations of the HF syndrome more comprehensively than the NPs.
While lower quality of HF treatment was associated with higher or increasing MR-proADM, patients on higher ACEi/ARB and beta-blocker doses at baseline and F6 had lower levels of this biomarker. This is consistent with findings that patients with a higher comorbidity burden tolerate up-titration of guideline-recommended cardiac drugs less well. 36 Additionally, reverse LV remodelling was significantly more common in study participants with consistently low MR-proADM levels. Taken together, these observations seem to confirm an interrelation between the likelihood of functional and morphological cardiac improvement, less systemic organ involvement, and better HF pharmacotherapy.
Data on the course of MR-proADM levels after AHF are scarce in the literature. We found that median MR-proADM levels remained almost unchanged throughout 18 months, while NP had already decreased significantly by F6. This provides further evidence that factors other than haemodynamics govern secretion of this hormone, and that MR-proADM reflects global patient risk better than the NPs, at least in patients surviving the early vulnerable phase after cardiac decompensation. Interestingly, the proportion of non-cardiac deaths increased over time in our study population. Consistent with a community-based HF surveillance study in which 43% of patients experienced non-cardiovascular deaths, 37 we observed a 50.6% non-cardiac death rate during the 18 month study period. This further underscores the prognostic relevance of non-cardiac comorbidities and may also explain the superior prognostic potential of MR-proADM during longer-term follow-up when patients become more haemodynamically stable.
Although median MR-proADM levels in the total cohort increased only slightly at F6 and then remained unchanged, levels in individual patients increased or decreased over time. Repeat MR-proADM assessment improved the prognostic yield because a substantial proportion of patients was reclassified into a more appropriate risk category using the F6 values, indicating that serial MR-proADM reassessment might be helpful in clinically stable chronic HF, despite the lack of significant changes in the entire . cohort. Interestingly, a previous study in which MR-proADM levels were determined at 24 and 72 h after admission suggested an additive value of these serial measurements to predict 28 day mortality also in the acute phase of cardiac decompensation.
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Strengths and limitations
Our baseline population approximates a population-based HF sample due to the broad inclusion criteria of the INH study. However, our findings cannot be generalized to subjects with new-onset structural heart disease or HF with preserved ejection fraction, who were excluded from the INH study. Furthermore, as in many other HF trials, women were under-represented in our study population. Of note, sex was not associated with MR-proADM levels suggesting other factors as mediators of the observed higher proportion of women in the upper tertiles.
Besides older age, a higher prevalence of various comorbidities in women (as demonstrated in a previous analysis from the INH study 38 ) might explain this finding. Biomarkers were assessed in a single core laboratory, ensuring consistency, and follow-up over 18 months was comprehensive. The high event rates observed allowed adjustment for multiple variables of proven prognostic importance, and the resulting base model provided a strong C-statistic for mortality. Still, we could not adjust for all potential confounders, and the characteristics selected might have influenced the results. Nevertheless, our clinical model was composed of variables that were previously shown to have independent prognostic significance and enhanced risk prediction when combined with the investigated biomarkers.
Biomarker measurements at F6 and F18 were only available in subsets of patients. Subjects who died early or were unable to attend follow-up were older, had more severe HF, and more comorbidities than those for whom follow-up biomaterials were available. However, patient groups were still quite large (F6, n = 599; F18, n = 477). Although the capacity for risk stratification established in healthier patients likely also applies to a sicker population, this remains unproven and constitutes another limitation of our study.
Given that the specific aim of our study was to characterize the incremental value of MR-proADM compared with the gold standard NP and the clinical base model for risk stratification in patients discharged from hospital after an episode of AHF, we did not include other biomarkers, e.g. cardiac troponins, in the current analysis and their possible additional value warrants further investigation.
Clinical implications and conclusions
Our results highlight the importance of systemic organ involvement impacting on disease progression in patients after AHF, which seems to be comprehensively captured by the novel biomarker MR-proADM. We showed significant associations with both cardiac and non-cardiac mortality risk as well as the occurrence of cardiac reverse remodelling. Our results suggest that MR-proADM might even enhance risk-stratification in HF patients more than the two NPs investigated in this study, whose respective prognostic potential proved comparable, as in previous investigations. 15, 16 Thus, MR-proADM may complement and enhance clinical judgment, a quality criterion called for by current biomarker guidelines. 39 Identification of individuals at highest risk for adverse outcomes and of patients more likely to have better outcomes could facilitate more targeted resource allocation, allowing for more aggressive diagnostic and comprehensive therapeutic interventions to be focused on patients who really need them. In this way MR-proADM assessment could contribute to improving real-world patient care. Whether other novel and promising biomarkers (e.g. somatostatin receptor 2), which reflect different pathophysiological pathways, add further prognostic value (alone or in combination with MR-proADM) has not been addressed, but deserves further investigation. Further prospective studies are required to better establish the role of MR-proADM in routine HF care.
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